GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Lux Health Tech Acquisition Corp (NAS:LUXAU) » Definitions » Debt-to-EBITDA

Lux Health Tech Acquisition (Lux Health Tech Acquisition) Debt-to-EBITDA : -0.25 (As of Jun. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Lux Health Tech Acquisition Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lux Health Tech Acquisition's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $0.48 Mil. Lux Health Tech Acquisition's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $0.00 Mil. Lux Health Tech Acquisition's annualized EBITDA for the quarter that ended in Jun. 2022 was $-1.88 Mil. Lux Health Tech Acquisition's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 was -0.25.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Lux Health Tech Acquisition's Debt-to-EBITDA or its related term are showing as below:

LUXAU' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.43   Med: -0.41   Max: -0.41
Current: -0.43

During the past 2 years, the highest Debt-to-EBITDA Ratio of Lux Health Tech Acquisition was -0.41. The lowest was -0.43. And the median was -0.41.

LUXAU's Debt-to-EBITDA is not ranked
in the Diversified Financial Services industry.
Industry Median: 5.42 vs LUXAU: -0.43

Lux Health Tech Acquisition Debt-to-EBITDA Historical Data

The historical data trend for Lux Health Tech Acquisition's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lux Health Tech Acquisition Debt-to-EBITDA Chart

Lux Health Tech Acquisition Annual Data
Trend Dec20 Dec21
Debt-to-EBITDA
N/A -0.41

Lux Health Tech Acquisition Quarterly Data
Aug20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Debt-to-EBITDA Get a 7-Day Free Trial - - -2.75 -0.43 -0.25

Competitive Comparison of Lux Health Tech Acquisition's Debt-to-EBITDA

For the Shell Companies subindustry, Lux Health Tech Acquisition's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lux Health Tech Acquisition's Debt-to-EBITDA Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Lux Health Tech Acquisition's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lux Health Tech Acquisition's Debt-to-EBITDA falls into.



Lux Health Tech Acquisition Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lux Health Tech Acquisition's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.484 + 0) / -1.183
=-0.41

Lux Health Tech Acquisition's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.477 + 0) / -1.876
=-0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2022) EBITDA data.


Lux Health Tech Acquisition  (NAS:LUXAU) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Lux Health Tech Acquisition Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lux Health Tech Acquisition's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Lux Health Tech Acquisition (Lux Health Tech Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
920 Broadway, 11th Floor, New York, NY, USA, 10010
Lux Health Tech Acquisition Corp is a blank check company.
Executives
Frederic H Moll director C/O INTUITIVE SURGICAL INC, 950 KIFER ROAD, SUNNYVALE CA 94086
Joshua Defonzo director, officer: Chief Executive Officer 1500 CORDILLERAS AVENUE, SAN CARLOS CA 94070
Peter Hebert director, 10 percent owner C/O LUX VENTURES, 295 MADISON AVE, 24TH FLOOR, NEW YORK NY 10017
J Robert Kerrey director NEW SCHOOL UNIVERSITY, 66 W. 12TH STREET, NEW YORK NY 10036
Josh Wolfe 10 percent owner C/O LUX HEALTH TECH ACQUISITION CORP., 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Bijan Salehizadeh director C/O NAVIMED CAPITAL, 1333 H STREET NW, SUITE 400 WEST, WASHINGTON DC 20005
Segolene Scarborough officer: CFO and Treasurer C/O LUX HEALTH TECH ACQUISITION CORP., 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Lux Encore Sponsor, Lp 10 percent owner C/O LUX HEALTH TECH ACQUISITION CORP., 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Lux Encore Holdings, Llc 10 percent owner C/O LUX HEALTH TECH ACQUISITION CORP., 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010

Lux Health Tech Acquisition (Lux Health Tech Acquisition) Headlines